Profile data is unavailable for this security.
About the company
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
- Revenue in INR (TTM)3.09bn
- Net income in INR81.31m
- Incorporated1987
- Employees986.00
- LocationBal Pharma LtdFour Mangoe LaneSurendra Mohan Ghosh SaraniBANGALORE 560052IndiaIND
- Phone+91 8 041379500
- Fax+91 8 022354057
- Websitehttps://www.balpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd | 1.06bn | 139.06m | 1.19bn | 121.00 | 8.54 | -- | 6.75 | 1.12 | 11.30 | 11.30 | 86.47 | -- | -- | -- | -- | 8,791,298.00 | -- | 13.79 | -- | 16.47 | 58.42 | 43.07 | 13.07 | 14.02 | -- | 137.75 | -- | -- | 5.58 | 12.57 | -7.88 | 22.90 | -4.68 | -- |
| Bal Pharma Ltd | 3.09bn | 81.31m | 1.22bn | 986.00 | 15.36 | -- | 6.66 | 0.3944 | 4.99 | 4.99 | 192.78 | -- | -- | -- | -- | 3,138,557.00 | -- | 1.95 | -- | 5.49 | 47.13 | 43.12 | 2.63 | 1.88 | -- | 1.12 | -- | 30.29 | -10.65 | 12.12 | -2.39 | -- | 29.98 | -- |
| Krebs Biochemicals And Industries Ltd | 230.23m | -228.62m | 1.28bn | 202.00 | -- | -- | -- | 5.54 | -10.60 | -10.60 | 10.68 | -74.60 | -- | -- | -- | 1,139,753.00 | -- | -16.90 | -- | -26.56 | 96.27 | 20.39 | -99.30 | -55.63 | 0.0359 | -2.42 | 3.65 | -- | -14.10 | 5.33 | -36.55 | -- | -17.65 | -- |
| Sotac Pharmaceuticals Ltd | 814.02m | 87.04m | 1.38bn | 67.00 | 15.88 | 2.48 | 9.12 | 1.70 | 7.87 | 7.87 | 73.61 | 50.39 | 0.6818 | 2.86 | 2.67 | 12,149,600.00 | 8.46 | 5.81 | 16.28 | 12.47 | 37.26 | 25.59 | 12.40 | 4.69 | 0.9737 | 2.30 | 0.3854 | -- | -6.59 | 27.66 | 124.25 | 146.89 | 11.66 | -- |
| Alpa Laboratories Limited | 1.14bn | 116.09m | 1.49bn | 453.00 | 12.85 | -- | 10.59 | 1.30 | 5.51 | 5.51 | 53.34 | -- | -- | -- | -- | 2,523,914.00 | -- | 8.59 | -- | 10.61 | 26.16 | 33.75 | 10.15 | 13.40 | -- | -17.25 | -- | -- | 3.41 | 5.52 | 16.25 | 60.11 | 34.92 | -- |
